Combined PMCT and TACE in the Therapy of Hepatocellular Carcinoma

SHAN Ren-feng,PENG Gui-zhu,ZHOU Fu-qing,RAO Xue-feng,WU Bo
DOI: https://doi.org/10.3969/j.issn.1009-8194.2009.02.019
2009-01-01
Abstract:Objective To evaluate the efficacy of percutaneous microwave coagulation therapy(PMCT) combined with transarterial chemoembolization(TACE) in the treatment of hepatocellular carcinoma(HCC).Methods59 HCC patients with a maximum of 3 total tumors and tumor ≤5 cm in diameter were selected in this study.These patients were randomly divided into 2 groups,39 underwent TACE following ultrasound-guided PMCT within 1-3 weeks(combined group),and 20 received PMCT alone(PMCT group).ResultsCDFI showed that the intratumoral blood flow was disappeared in 94.9%(37/39)and 95.0%(19/20) in the combined group and PMCT group respectively.Serum AFP level was normalized in 34(87.2%) cases of combined group,and 16(80.0%) cases of PMCT group.The 1-,2-,and 3-year survival rate of combined group and PMCT group were 97.4%(38/39),89.7%(35/39),82.0%(32/39) and 90.0(18/20),80.0%(16/20),70.0%(14/20)respectively(P<0.05).The 1-,2-and 3-year cumulative recurrence rate of combined group and PMCT group were 7.7%(3/39),20.5%(8/39),30.8%(12/39) and 10.0%(2/20),30.0%(6/20),40.0%(8/20)respectively(P<0.05).The accident rate of fever and pain in the 2 groups were 61.5%(24/39),60%(12/20),25.6%(10/39),30%(6/20)(P>0.05).ConclusionThe combination of PMCT and TACE is a safe and effective therapy for small HCC,significantly increasing the rate of complete tumor necrosis and reducing recurrence.
What problem does this paper attempt to address?